epirubicin has been researched along with Cells, Neoplasm Circulating in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (27.59) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 12 (41.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Gui, A; Li, Z; Ling, F; Ma, S; Sun, Y | 1 |
| Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Malamos, N; Mavroudis, D; Papakotoulas, P; Politaki, E; Polyzos, A; Tryfonidis, K; Xenidis, N | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Bendigtsen Schirmer, C; Borgen, E; Falk, RS; Kersten, C; Mjaaland, I; Naume, B; Risberg, T; Rypdal, MC; Sommer, HH; Synnestvedt, M; Sætersdal, AB; Vindi, L; Weyde, K; Wiedswang, G; Wist, EA | 1 |
| Bachelot, T; Bidard, FC; Bonneterre, J; Campone, M; Charafe-Jauffret, E; Ferrero, JM; Gligorov, J; Hernandez, J; Lerebours, F; Lévy, C; Petit, T; Pierga, JY; Roché, H; Viens, P | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K | 1 |
| Andre, F; Autret, A; Bachelot, T; Bertucci, F; Bidard, FC; Boher, JM; Bonneterre, J; Campone, M; Charafe-Jaufret, E; Dalenc, F; Eymard, JC; Ferrero, JM; Gligorov, J; Hardy-Bessard, AC; Kerbrat, P; Lemonnier, J; Lerebours, F; Levy, C; Lortholary, A; Mouret-Reynier, MA; Petit, T; Pierga, JY; Proudhon, C; Romieu, G; Soulie, P; Viens, P | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Eidtmann, H; Fehm, T; Hilfrich, J; Holms, F; Huober, J; Komor, M; Loibl, S; Müller, V; Pantel, K; Rau, T; Riethdorf, S; Roller, M; Schrader, I; Tesch, H; Untch, M; von Minckwitz, G; Zhang, L | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Koshino, T; Sakita, I; Soma, I; Yoshida, T | 1 |
| Asahara, S; Fujita, N; Fujita, R; Ikari, T; Kamei, A; Sato, E; Shimizu, M; Takano, K | 1 |
| Fukami, Y; Hasegawa, H; Hiromatsu, T; Itazu, K; Kawai, K; Komatsu, S; Sakamoto, E; Tabata, T | 1 |
| Araki, K; Haruno, M; Ogawa, Y; Sakai, K; Shimamura, R; Tanaka, H | 1 |
| Anker, G; Bergh, J; Drageset, V; Erikstein, B; Kvalheim, G; Lundgren, S; Nesland, JM; Skovlund, E; Sommer, H; Wist, E | 1 |
| Dengler, R; Fröhlich, F; Kroll, T; Lobodasch, K; Pachmann, K; Pachmann, U; Rengsberger, M; Schubert, R | 1 |
| Czerwenka, K; Kubista, E; Kurz, C; Nagele, F; Obermair, A; Schemper, M; Sevelda, P | 1 |
| Bargou, R; Dörken, B; Hildebrandt, M; Körner, IJ; Krahl, D; Mapara, MY; Reichardt, P | 1 |
| Ebara, M; Endo, T; Kimura, K; Nakamura, H; Saisho, H; Yasuhara, K; Yoshikawa, M | 1 |
| Ebisui, C; Hirai, T; Kanai, T; Kouro, T; Miyamoto, A; Murai, N; Murata, A; Okazaki, M; Tada, M | 1 |
| Sakata, Y; Tsushima, K | 1 |
| Dalay, N; Inanç, S; Onat, H; Saip, P; Yazici, H | 1 |
| Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E | 1 |
| Bashford, J; Basser, RL; Begley, CG; Cebon, J; Collins, JP; Durrant, S; Fox, RM; Green, MD; Juttner, CA; Keefe, D; Kotasek, D; Maher, DW; Olver, I; Russell, I; Sheridan, WP; Szer, J; To, LB | 1 |
| Ahn, MJ; Cho, KS; Choi, IY; Joh, EK; Kim, HC; Kim, HS; Kim, IS; Kim, SH; Kim, SY; Lee, JA; Lee, YS; Lee, YY; Noh, YH; Park, YS; Shin, DB; Suh, CW | 1 |
| Maeda, M; Tazawa, J | 1 |
2 review(s) available for epirubicin and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Radiation therapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Epirubicin; Female; Humans; Iodized Oil; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Portal Vein; Prognosis; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2001 |
16 trial(s) available for epirubicin and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diarrhea; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Neutropenia; Receptor, ErbB-2; Survival Rate; Taxoids; Thrombocytopenia; Young Adult | 2013 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Keratins; Ki-67 Antigen; Middle Aged; Neoplastic Cells, Circulating; Norway; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Taxoids; Time Factors; Treatment Failure | 2014 |
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2015 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2017 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult | 2017 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorescent Antibody Technique; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Keratins; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Treatment Outcome | 2006 |
[The value of the "vascular invasion" factor for prognosis of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Muscle, Smooth, Vascular; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 1994 |
Investigation of the molecular changes during chemotherapy in non-Hodgkin's lymphoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Genes, bcl-2; Genes, Immunoglobulin; Humans; Immunoglobulin Joining Region; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Prednisolone; Translocation, Genetic; Vincristine | 1998 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Mitoxantrone; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Thiotepa | 1999 |
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Recombinant Proteins; Survival Rate | 1999 |
Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: multicenter trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2001 |
11 other study(ies) available for epirubicin and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Predictive Value of Tests; Prognosis; ROC Curve | 2017 |
Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Carcinoma; Cell Count; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Tamoxifen; Treatment Outcome | 2017 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
[A case of Vp3 hepatocellular carcinoma with a good QOL after multidisciplinary treatments].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Doxorubicin; Embolization, Therapeutic; Epirubicin; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplastic Cells, Circulating; Quality of Life; Tomography, X-Ray Computed | 2004 |
[A case of diffuse type of hepatocellular carcinoma with tumor thrombosis of inferior vena cava (Vv3) and main trunk of portal vein (Vp4), showing marked response to transcatheter arterial chemoembolization with degradable starch microspheres (DSM-TACE)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule; Epirubicin; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplastic Cells, Circulating; Portal Vein; Starch; Vena Cava, Inferior | 2004 |
[A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Papillary; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Follow-Up Studies; Humans; Leuprolide; Lung Neoplasms; Mastectomy, Radical; Neoplastic Cells, Circulating; Tamoxifen; Vena Cava, Inferior | 2005 |
[A case of hepatocellular carcinoma with tumor thrombi in the first branch of the portal vein and hepatic vein trunks treated by transcatheter hepatic arterial chemoembolization and hepatic arterial infusion chemotherapy--two years and six months follow-u
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Drug Administration Schedule; Epirubicin; Fluorouracil; Follow-Up Studies; Hepatic Artery; Hepatic Veins; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Male; Mitomycin; Neoplastic Cells, Circulating; Portal Vein; Thrombosis | 2005 |
An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cell Count; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Epithelial Cells; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prognosis; Remission Induction; Survival Rate; Tamoxifen; Taxoids | 2008 |
Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; DNA, Complementary; DNA, Neoplasm; Epirubicin; ErbB Receptors; Etoposide; Evaluation Studies as Topic; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunoenzyme Techniques; Immunomagnetic Separation; Keratins; Leukapheresis; Melphalan; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Transplantation Conditioning | 1997 |
[Long-term survival cases of hepatocellular carcinoma with portal tumor thrombus by repeated arterial infusion chemotherapy using implantable port system].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Epirubicin; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Portal System | 1997 |
[A case report of Vp3 hepatocellular carcinoma responding to multidisciplinary treatment].
Topics: Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Epirubicin; Hepatic Artery; Humans; Iodized Oil; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Portal System | 1997 |